ncAA Incorporated Peptide Vaccine Development

Leveraging the power of genetic code expansion (GCE) technology, the site-specific incorporation of non-canonical amino acids (ncAAs) has emerged as a transformative approach in the development of next-generation peptide vaccines. By transcending the limitations of the 20 standard amino acids, this methodology allows for the precise introduction of unique chemical moieties into antigenic sequences, thereby modulating immunogenicity and stability. At the forefront of this field, our company operates as a pioneering research service provider. Through our proprietary GCEngine platform, we provide a robust solution for pharmaceutical R&D, facilitating the transition from theoretical molecular design to validated preclinical applications.

Overview of ncAA Incorporated Peptide Vaccines

Traditional peptide vaccines can face challenges related to stability, immunogenicity, and precise presentation of target epitopes. ncAA-incorporated peptide vaccines are engineered by integrating non-canonical amino acids at specific positions within the peptide antigen sequence. These ncAAs can introduce novel side chains that are not found in nature, providing unique chemical functionalities. These functionalities can be utilized for site-specific conjugation to immunogenic carriers, fluorescent probes, or other moieties, for stabilizing the peptide structure, or for mimicking specific post-translational modifications critical for immune recognition. This approach allows for the rational design of next-generation vaccine candidates with enhanced properties and controlled antigen presentation.

Key Advantages of ncAA Incorporated Peptide Vaccines

Our Services

Driven by the leading GCEngine platform, our ncAA-incorporated peptide vaccine development services encompass every stage of the design and validation process. The service encompasses the identification and optimization of orthogonal aaRS/tRNA pairs specific for specified ncAAs, followed by rigorous validation of ncAA incorporation efficiency in both in vitro translation systems and live bacterial or mammalian host organisms. We leverage this platform to offer end-to-end support, from the initial design of ncAA-containing epitopes and selection of optimal conjugation chemistries to the generation and preliminary immunological evaluation of the novel vaccine conjugates.

Workflow of ncAA Incorporated Peptide Vaccine Development

• Epitope Analysis & ncAA Selection: Collaborative design of target peptide sequences, identifying optimal sites for ncAA incorporation based on structural, functional, and immunological objectives.
• Orthogonal Pair Screening & Engineering: Utilizing our high-throughput platform to identify or evolve efficient and specific orthogonal aaRS/tRNA pairs for the chosen ncAA.
• Validation of ncAA Incorporation: Synthesis of the ncAA-incorporated peptide vaccine candidate using cell-free protein synthesis (CFPS) systems or engineered microbial hosts. Successful incorporation is rigorously verified by LC-MS/MS and HPLC.
• Vaccine Construct Assembly & Conjugation: Site-specific conjugation of the purified ncAA-peptide to a selected carrier protein, adjuvant system, or nanomaterial delivery platform using the unique reactivity of the ncAA.
• Preclinical Immunogenicity & Efficacy Testing: Evaluation of the conjugate vaccine's ability to elicit target-specific immune responses in relevant cellular and animal models, including assessment of antigen-specific T-cell activation, antibody titers, cytokine profiling, and in vivo efficacy in relevant disease models (e.g., tumor challenge or infection models).

ncAA-Incorporated Peptide Vaccine Library Services

Beyond bespoke candidate development, our GCEngine platform uniquely enables the support of the construction of diverse ncAA-incorporated peptide vaccine libraries. We can rapidly generate and screen extensive arrays of peptide antigen variants, each systematically incorporating distinct ncAAs at defined positions or carrying different bio-orthogonal handles.

This powerful approach allows systematic evaluation of key parameters, such as proteolytic stability, MHC binding affinity, carrier conjugation efficiency, and immunogenic potency. By transforming vaccine optimization into a screenable process, our library service can accelerate the identification of lead candidates with the optimal combination of chemical and immunological properties, de-risking and expediting your early-stage discovery pipeline.

Applications and Design Strategies of ncAA Incorporated Peptide Vaccines

The versatility of ncAA incorporation enables the development of diverse peptide vaccine platforms tailored to specific therapeutic applications and delivery requirements. These include therapeutic vaccines targeting tumor-associated antigens, prophylactic vaccines against infectious pathogens, and immunomodulatory vaccines for autoimmune conditions.

• TAA-Targeted Vaccines
• Post-Translational Modification (PTM) Mimetic Vaccines
• Bio-orthogonal "Click" Conjugated Vaccines

• Metabolically Stabilized Peptidomimetic Vaccines
• Conformationally Constrained Vaccines
• Multi-Epitope Chimeric Vaccines

Contact Us

By integrating deep expertise in GCE with a focused application for vaccine innovation, we provide a unique and powerful suite of services for developing next-generation peptide-based immunotherapies. Our GCEngine platform is designed to translate complex scientific concepts into high-quality vaccine candidates with enhanced properties. For collaborative discussions on how our ncAA-incorporated peptide vaccine development services can advance your specific program, please reach out to us.

Reference

1. Ao, Yuanyun et al. "Bioorthogonal click labeling of an amber-free HIV-1 provirus for in-virus single molecule imaging." Cell chemical biology 31.3 (2024): 487-501.

All our services are exclusively intended for preclinical research purposes. They are not intended for diagnostic, therapeutic, or patient management applications.